As AAOS Sees Record Growth in Fracture & Trauma Registry Data Submissions, Technology Partnership Offering with PatientIQ Expands to Include Nationwide Participation Options

On the heels of a successful technology pilot program with PatientIQ, the American Academy of Orthopaedic Surgeons (AAOS) has seen a rapid increase in data submissions to the Fracture & Trauma Registry (FTR). Through the submission and analysis of data to the FTR, healthcare systems and orthopaedic surgeons can actively utilize the knowledge gained to improve outcomes and the quality of orthopaedic care in turn supporting highly informed decision-making and quality improvement.

AAOS partnered with PatientIQ in December 2022 to integrate its cloud-based platform directly with FTR participants’ electronic health records (EHR) and simplify the process to collect and submit registry data for five of the more common fractures in the U.S. Within the first eight months, the partnership yielded a substantial increase in data submitted to the FTR. By expanding the participation options to include the PatientIQ solution, the FTR is reducing barriers to tracking evidence-based practices and advancing the delivery of musculoskeletal care. To date, there are 35 participating sites contributing to the FTR.

Michael J. Gardner, MD, FAAOS,
chair of the AAOS Fracture & Trauma Registry Steering Committee
….

“Due to the complexity of having five modules in one registry, we recognized potential data challenges for some sites. We collaborated with PatientIQ to help mitigate the burden and enhance data submission.Consequently, data within the registry has increased significantly and is helping fuel new momentum within the registry.”

Automating Registry Participation Within a Matter of Weeks
Utilizing FHIR-based APIs and other live integration functionality, PatientIQ can help extract and translate critical health information into registry-compliant specifications and submit it on behalf of participating orthopaedic surgeons. In doing so, the platform eases the administrative and technological burden associated with submitting procedural, post operative and patient-reported outcomes to the FTR.

Click here to watch a webinar discussing one customer’s journey with the FTR Powered by PatientIQ.

Hospital sites, ambulatory service centers or institutions where fracture and trauma-related incidents are treated are invited to participate in the FTR. Enrollment through PatientIQ is encouraged, but optional. To get involved with the FTR, email an AAOS Registry engagement associate at RegistryEngagement@aaos.org, call 847-292-0530, or click here. For more information about PatientIQ, visit www.patientiq.io.

SourceAAOS

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.